Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    APBA2
Previous Study | Return to List | Next Study

Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy Smokers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03259607
Recruitment Status : Completed
First Posted : August 23, 2017
Last Update Posted : January 3, 2019
Sponsor:
Collaborator:
Janssen (China) Research & Development Center
Information provided by (Responsible Party):
Johnson & Johnson Consumer and Personal Products Worldwide ( McNeil AB )

Brief Summary:

This is a research study to verify the same effectiveness and safety profile for the test products, nicotine 2 mg gum and nicotine 4 mg gum, as for the already approved products, Nicorette Mint 2 mg gum and Nicorette Mint 4 mg gum (reference products), in a standardized mode. This verification is done in a so-called bioequivalence study, which means that the same amount of the same active substance (nicotine), in the same dosage form, for the same route of administration, and meeting the same or comparable standards is performed.

During the study visits, blood samples will be drawn to measure the level of the substance in the blood to verify that the two test products are comparable to the reference products.

Tolerability of the treatments will be evaluated based on reported and observed adverse events.


Condition or disease Intervention/treatment Phase
Tobacco Dependence Drug: Nicorette Extra Mint 2 mg Gum Drug: Nicorette Mint 2 mg Gum Drug: Nicorette Extra Mint 4mg Gum Drug: Nicorette Mint 4 mg Gum Phase 1

Detailed Description:

This is a single-center, randomized, single-dose open-label, cross-over study in 76 healthy males and females in total. The investigational products (IPs), i.e., Nicorette Extra Mint Gum 2 and 4 mg, and Nicorette Mint Gum 2 and 4 mg, will be given as single doses at separate treatment visits. Investigational treatments will be separated by at least 36 hours.

Blood samples for determination of nicotine will be drawn pre-dose (within 5 minutes of administering, i.e., start of chewing) and at 5, 10, 15, 20, 30, 45, and 60 minutes, as well as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration.

Used gums will be collected and analyzed to determine the amount of remaining nicotine.

Any Adverse Events (AEs) that may occur will be registered.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: single-center, randomized, single-dose, open-label, cross-over study
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Single Dose, Randomized, Four Period, Fasting, Crossover Study to Assess Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Mint Gum 2 and 4 mg - in Adult Healthy Male and Female Smokers
Actual Study Start Date : August 14, 2017
Actual Primary Completion Date : December 25, 2017
Actual Study Completion Date : January 9, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment A
Nicorette Extra Mint 2 mg Gum
Drug: Nicorette Extra Mint 2 mg Gum
A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.

Active Comparator: Treatment B
Nicorette Mint 2 mg Gum
Drug: Nicorette Mint 2 mg Gum
A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.

Experimental: Treatment C
Nicorette Extra Mint 4 mg Gum
Drug: Nicorette Extra Mint 4mg Gum
A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.

Active Comparator: Treatment D
Nicorette Mint 4 mg Gum
Drug: Nicorette Mint 4 mg Gum
A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.




Primary Outcome Measures :
  1. Peak Plasma Concentration (Cmax) of nicotine. [ Time Frame: At baseline, 5, 10, 15, 20, 30, 45, and 60 minutes, as well as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration. ]
    The maximum observed plasma concentration (Cmax).

  2. Area under the plasma concentration versus time curve (AUCt) from start of nicotine administration until the last measurable concentration. [ Time Frame: At baseline, 5, 10, 15, 20, 30, 45, and 60 minutes, as well as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration. ]
    AUCt is defined as area under the plasma concentration versus time curves from start of drug administration until the last measureable concentration.

  3. Area under the plasma concentration versus time curve (AUC∞) of nicotine. [ Time Frame: At baseline, 5, 10, 15, 20, 30, 45, and 60 minutes, as well as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration. ]
    AUC∞ is defined as area under the plasma concentration versus time curves from start of drug administration until the nicotine plasma concentration is negligible (infinity).


Secondary Outcome Measures :
  1. The extrapolated part of area under the plasma concentration versus time curve (AUC∞) of nicotine. [ Time Frame: Extrapolation from 12 hours after start of drug administration until 48 hours. ]
    The area under the plasma concentration versus time curves from start of drug administration until 48 hours (infinity).

  2. The time at which the maximum nicotine concentration (Cmax) occurs (Tmax). [ Time Frame: At baseline, 5, 10, 15, 20, 30, 45, and 60 minutes, as well as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration. ]
    Tmax is defined as the time point at which the maximum nicotine concentration (Cmax) occurs.

  3. Determination of the terminal elimination rate constant (lambda_z) for nicotine. [ Time Frame: At baseline, 5, 10, 15, 20, 30, 45, and 60 minutes, as well as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration. ]
    The rate at which the drug is removed from the body system.

  4. The plasma half-life (t1/2) of nicotine. [ Time Frame: At baseline, 5, 10, 15, 20, 30, 45, and 60 minutes, as well as 1.5, 2, 4, 6, 7, 8, 9, and 10 hours after start of administration. ]
    The time taken for the nicotine plasma concentration to fall to half its original value.

  5. Amount of nicotine extracted from Nicorette Mint 2 mg gums. [ Time Frame: After 30 minutes of chewing. ]
    The residual amount of nicotine in the chewed gums will be analyzed and subtracted from the original amount of nicotine in the gums, and summarized descriptively.

  6. Amount of nicotine extracted from Nicorette Mint 4 mg gums. [ Time Frame: After 30 minutes of chewing. ]
    The residual amount of nicotine in the chewed gums will be analyzed and subtracted from the original amount of nicotine in the gums, and summarized descriptively.

  7. Amount of nicotine extracted from Nicorette Extra Mint 2 mg gums. [ Time Frame: After 30 minutes of chewing. ]
    The residual amount of nicotine in the chewed gums will be analyzed and subtracted from the original amount of nicotine in the gums, and summarized descriptively.

  8. Amount of nicotine extracted from Nicorette Extra Mint 4 mg gums. [ Time Frame: After 30 minutes of chewing. ]
    The residual amount of nicotine in the chewed gums will be analyzed and subtracted from the original amount of nicotine in the gums, and summarized descriptively.

  9. Percentage of Subjects with Treatment-Emergent Adverse Events after single-dose administration of investigational product. [ Time Frame: From first dose received up to 2.5 weeks + 30 days follow up after study completion for any unresolved adverse events. ]
    Percentage of subjects experiencing treatment-emergent adverse events by treatment, system organ class and preferred term.

  10. Percentage of Subjects with Treatment-Emergent Adverse Events after single-dose administration of investigational product - by worst-case severity. [ Time Frame: From first dose received up to 2.5 weeks + 30 days follow up after study completion for any unresolved adverse events. ]
    Percentage (%) of subjects experiencing treatment-emergent adverse events by treatment, system organ class, preferred term and severity.

  11. Percentage of Subjects with common treatment-emergent adverse events (AEs) after single-dose administration of Investigational product. [ Time Frame: From first dose received up to 2.5 weeks + 30 days follow up after study completion for any unresolved adverse events. ]
    Percentage (%) of subjects with commonly reported treatment-emergent adverse events by system organ class and preferred term.

  12. Percentage of Subjects with treatment-related adverse events (AEs) after single-dose administration of investigational product. [ Time Frame: From first dose received up to 2.5 weeks + 30 days follow up after study completion for any unresolved adverse event. ]
    Percentage (%) of subjects experiencing treatment-related adverse events by treatment, system organ class and preferred term.

  13. Percentage of Subjects with treatment-related adverse events (AEs) after single-dose administration of investigational product - by worst-case severity. [ Time Frame: From first dose received up to 2.5 weeks + 30 days follow up after study completion for any unresolved adverse events. ]
    Percentage (%) of subjects experiencing treatment-related adverse events by treatment, system organ class, preferred term and severity.

  14. Percentage of Subjects with treatment-emergent serious adverse events (SAEs). [ Time Frame: From first dose received up to 2.5 weeks + 30 days follow up after study completion. ]
    Percentage (%) of subjects experiencing treatment-emergent serious adverse events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male subjects between the ages of 18 and 55 years, inclusive, and healthy female subjects between the ages of 18 and 45 years, inclusive. Health is defined as the absence of clinically relevant abnormalities identified by a detailed medical history, physical examination, blood pressure and pulse rate measurements, 12-lead electrocardiogram (ECG) as well as clinical laboratory tests, as judged by the Investigator or an authorized physician.
  2. Smoking of at least 10 cigarettes daily for at least one year preceding inclusion.
  3. Subjects will have a body mass index (BMI) between 19 and 25 (inclusive) kg/m2 and a body weight >50 kg.
  4. Females of childbearing potential must have a negative pregnancy test at the screening visit.
  5. Male or non-pregnant, non-lactating female agree to the contraceptive requirements including male's and female partner's use of a highly effective methods of birth control for at least 3 months before the study, during the study and for 30 days after the last dose of the study drug).
  6. A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study before participating in any study-specific procedures.
  7. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol.

Exclusion Criteria:

  1. Use of medications other than contraceptives specified in Inclusion Criterion 4. Vitamins, dietary, and herbal supplements must be discontinued at least two days before the first dose of study medication.
  2. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, Human Immunodeficiency Virus (HIV) or syphilis.
  3. Hypersensitivity to the ingredients/components of any of the IPs.
  4. History of alcoholism, as judged by the Investigator, within the past 6 months preceding this study and/or presenting a positive respiratory alcohol test (breathalyzer) at the screening visit.
  5. History of drug abuse or presenting a positive drug screening test for psychoactive drugs and narcotic substances at screening visit.
  6. Treatment with an IP within 3 months preceding this study.
  7. Donation or loss of blood within 3 months preceding this study if the estimated lost blood volume equaled or exceeded 200 mL.
  8. Impaired chewing capability as assessed by oral examination (e.g. dentures, significant oral ulceration) or impaired salivary secretion (e.g. Sicca syndrome). Piercing of tongue and lips is considered to impair oral function.
  9. Preplanned surgery or procedures during the study period, if this may interfere with the conduct of the study.
  10. Relationship to persons involved directly with the conduct of the study (i.e. PI; Sub investigators; study coordinators; other study personnel; employees or contractors of the sponsor or Johnson & Johnson (J&J) subsidiaries; and the families of each).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03259607


Locations
Layout table for location information
China
Beijing Hospital, No.1
Beijing, China, 100730
Sponsors and Collaborators
McNeil AB
Janssen (China) Research & Development Center
Investigators
Layout table for investigator information
Principal Investigator: Shi Aixin, M. Pharm BeiJing Hospital, No.1, Beijing, China.

Additional Information:
Layout table for additonal information
Responsible Party: McNeil AB
ClinicalTrials.gov Identifier: NCT03259607     History of Changes
Other Study ID Numbers: CO-160307090208-SCCT
10258820NIK1001 ( Other Identifier: Janssen TMS )
First Posted: August 23, 2017    Key Record Dates
Last Update Posted: January 3, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Johnson & Johnson Consumer and Personal Products Worldwide ( McNeil AB ):
Bioequivalence
Additional relevant MeSH terms:
Layout table for MeSH terms
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action